1. 3055 A prognostic model for platinum-doublet regimens as second-line chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients. (September 2015) Authors: Shi, Y.; Mo, H.; Hao, X.; Liu, Y.; Wang, L.; Hu, X.; Xu, J.; Yang, S.; Xing, P.; Shi, Y.; Jia, B.; Wang, Y.; Li, J.; Wang, H.; Wang, Z.; Sun, Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S614 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. Issue 12 (16th July 2015) Authors: Lawitz, E.; Freilich, B.; Link, J.; German, P.; Mo, H.; Han, L.; Brainard, D. M.; McNally, J.; Marbury, T.; Rodriguez‐Torres, M. Journal: Journal of viral hepatitis Issue: Volume 22:Issue 12(2015) Page Start: 1011 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. Issue 11 (18th March 2015) Authors: Hedskog, C.; Dvory‐Sobol, H.; Gontcharova, V.; Martin, R.; Ouyang, W.; Han, B.; Gane, E. J.; Brainard, D.; Hyland, R. H.; Miller, M. D.; Mo, H.; Svarovskaia, E. Journal: Journal of viral hepatitis Issue: Volume 22:Issue 11(2015) Page Start: 871 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Issue 1 (26th October 2015) Authors: Lai, C. L.; Wong, V. W.‐S.; Yuen, M. F.; Yang, J. C.; Knox, S. J.; Mo, H.; Han, L. L.; Brainard, D. M.; Chan, H. L. Y. Journal: Alimentary pharmacology & therapeutics Issue: Volume 43:Issue 1(2016) Page Start: 96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗